Home Cart 0 Sign in  
X

[ CAS No. 62642-62-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 62642-62-0
Chemical Structure| 62642-62-0
Chemical Structure| 62642-62-0
Structure of 62642-62-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 62642-62-0 ]

Related Doc. of [ 62642-62-0 ]

Alternatived Products of [ 62642-62-0 ]

Product Details of [ 62642-62-0 ]

CAS No. :62642-62-0 MDL No. :MFCD01167722
Formula : C12H15NO3 Boiling Point : -
Linear Structure Formula :- InChI Key :QYBXZYYECZFQRX-UHFFFAOYSA-N
M.W : 221.25 Pubchem ID :703507
Synonyms :

Calculated chemistry of [ 62642-62-0 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.42
Num. rotatable bonds : 3
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 63.38
TPSA : 49.77 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -8.48 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.01
Log Po/w (XLOGP3) : -1.17
Log Po/w (WLOGP) : 0.68
Log Po/w (MLOGP) : 1.0
Log Po/w (SILICOS-IT) : 1.65
Consensus Log Po/w : 0.84

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.55
Solubility : 61.8 mg/ml ; 0.279 mol/l
Class : Very soluble
Log S (Ali) : 0.62
Solubility : 918.0 mg/ml ; 4.15 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -2.37
Solubility : 0.946 mg/ml ; 0.00428 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.51

Safety of [ 62642-62-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 62642-62-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 62642-62-0 ]
  • Downstream synthetic route of [ 62642-62-0 ]

[ 62642-62-0 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 68453-56-5 ]
  • [ 62642-62-0 ]
YieldReaction ConditionsOperation in experiment
79.57% With water; sodium hydroxide In methanol at 0 - 20℃; To a stirred solution of methyl 4-(morpholinomethyl)benzoate (step 1, 4.0 g, 17.0020 mmol, 1.0 eq) in MeOH (40 mL) at 0 oc was added aqueous 1N NaOH solution (136.0 mL,136.0 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight.After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0°C, neutralized with 1N HCl and evaporated under reduced pressure. To the resulting solid,methanol (40 mL) and dichloromethane (60 mL) were added and stirred at room temperature25 for 30 minutes. The mixture was filtered and the filtrate was evaporated under reducedpressure. The above procedure was repeated twice and the obtained solid (3.0 g, yield:79.57percent) was used as such for next step without further purification. 1H NMR (300 MHz,CDCh): 8 ppm 8.04 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 3.81 (m, 4H), 3.71 (s, 2H),2.62 (m, 4H); ESI-MS: m/z 222.01 (M+Ht
Reference: [1] Patent: WO2018/29604, 2018, A1, . Location in patent: Page/Page column 45
[2] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 2, p. 179 - 190
  • 2
  • [ 110-91-8 ]
  • [ 1642-81-5 ]
  • [ 62642-62-0 ]
YieldReaction ConditionsOperation in experiment
70% for 24 h; Heating / reflux 4.04 g (1 equivalent) of α-chloroparatoluic acid and 4.13 g (2 equivalents) of morpholine are placed in solution in 150 mL of toluene. The reaction mixture is taken to reflux for 24 hours The morpholine hydrochloride is eliminated by warm filtration through a Buchner. The product crystallizes from the filtrate at ambient temperature. After filtration and drying, 3.63 g of product is obtained in the form of a white powder (Yield=70percent).NMR 1H (250 MHz, DMSOD6): δ 7.84 and 7.37 (2d, 2x2H, ArH), 3.53 (t, 4H, CH2OCH2), 3.48 (s, 2H, Ar-CH2-), 2.31 (t, 4H, CH2-N-CH2-).MS ES+: m/e 222 ([M+H]+, 100).
Reference: [1] Tetrahedron Letters, 1991, vol. 32, # 50, p. 7385 - 7388
[2] Patent: US6972343, 2005, B1, . Location in patent: Page/Page column 13
[3] Bulletin of the Korean Chemical Society, 2015, vol. 36, # 8, p. 1959 - 1965
[4] Medicinal Chemistry Research, 2016, vol. 25, # 10, p. 2205 - 2213
  • 3
  • [ 110-91-8 ]
  • [ 6232-88-8 ]
  • [ 62642-62-0 ]
YieldReaction ConditionsOperation in experiment
75% for 0.166667 h; Step 1: 4- (MORPHOLINOMETHYL) benzoic acid (240) [0389] To a stirred solution of 4-bromomethyl-benzoic acid (239,1. 5 g, 6.78 MMOL) in THF (15 mL) was added morpholine (0.61 mL, 6.78 MMOL). The reaction mixture was allowed to stir for 10 minutes before the resulting white precipitate was filtered off and discarded. The filtrate was evaporated under reduced pressure and the remaining solid was dried under vacuum to afford the title compound 240 as a white solid (1.15 g, 75 percent YIELD). H NMR: (DMSO) 8 7.89-7. 86 (m, 2H), 7.52 (d. J=8.4 Hz, 1H), 7.41 (d, J=8. 0 Hz, 1H), 4.12 (s, 2H), 3.75-3. 72 (m, 1H), 3.56-3. 58 (m, 4H), 3.10-3. 07 (m, 1H), 2.45-2. 35 (m, 2H).
Reference: [1] Patent: WO2005/30704, 2005, A1, . Location in patent: Page/Page column 224
  • 4
  • [ 1571-08-0 ]
  • [ 62642-62-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 2, p. 179 - 190
  • 5
  • [ 2417-72-3 ]
  • [ 62642-62-0 ]
Reference: [1] Patent: WO2018/29604, 2018, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 62642-62-0 ]

Aryls

Chemical Structure| 17847-26-6

[ 17847-26-6 ]

4-((Dimethylamino)methyl)benzoic acid hydrochloride

Similarity: 0.83

Chemical Structure| 514209-40-6

[ 514209-40-6 ]

2-(4-Methylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 106261-48-7

[ 106261-48-7 ]

4-((4-Methylpiperazin-1-yl)methyl)benzoic acid

Similarity: 0.82

Chemical Structure| 914349-54-5

[ 914349-54-5 ]

2-(4-Ethylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 106261-49-8

[ 106261-49-8 ]

4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride

Similarity: 0.81

Carboxylic Acids

Chemical Structure| 17847-26-6

[ 17847-26-6 ]

4-((Dimethylamino)methyl)benzoic acid hydrochloride

Similarity: 0.83

Chemical Structure| 514209-40-6

[ 514209-40-6 ]

2-(4-Methylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 106261-48-7

[ 106261-48-7 ]

4-((4-Methylpiperazin-1-yl)methyl)benzoic acid

Similarity: 0.82

Chemical Structure| 914349-54-5

[ 914349-54-5 ]

2-(4-Ethylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 106261-49-8

[ 106261-49-8 ]

4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride

Similarity: 0.81

Related Parent Nucleus of
[ 62642-62-0 ]

Aliphatic Heterocycles

Chemical Structure| 514209-40-6

[ 514209-40-6 ]

2-(4-Methylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 106261-48-7

[ 106261-48-7 ]

4-((4-Methylpiperazin-1-yl)methyl)benzoic acid

Similarity: 0.82

Chemical Structure| 914349-54-5

[ 914349-54-5 ]

2-(4-Ethylpiperazin-1-ylmethyl)benzoic acid

Similarity: 0.82

Chemical Structure| 42106-48-9

[ 42106-48-9 ]

2-Morpholinobenzoic acid

Similarity: 0.80

Chemical Structure| 215309-00-5

[ 215309-00-5 ]

3-Morpholinobenzoic acid

Similarity: 0.78

Morpholines

Chemical Structure| 42106-48-9

[ 42106-48-9 ]

2-Morpholinobenzoic acid

Similarity: 0.80

Chemical Structure| 690632-76-9

[ 690632-76-9 ]

2-Morpholino-5-(1H-pyrrol-1-yl)benzoic acid

Similarity: 0.79

Chemical Structure| 215309-00-5

[ 215309-00-5 ]

3-Morpholinobenzoic acid

Similarity: 0.78

Chemical Structure| 10316-00-4

[ 10316-00-4 ]

4-Benzylmorpholine

Similarity: 0.72

Chemical Structure| 91271-84-0

[ 91271-84-0 ]

(4-(Morpholinomethyl)phenyl)methanamine

Similarity: 0.72